Abstract Background Due to competing health priorities and limited resources, many low-income countries, even those with a high disease burden, are not able to introduce pneumococcal conjugate vaccines. Objective To determine the cost-utility of 10- and 13-valent pneumococcal conjugate vacci

Abstract Real-world effectiveness studies are important for monitoring performance of COVID-19 vaccination programmes and informing COVID-19 prevention and control policies. We aimed to synthesise methodological approaches used in COVID-19 vaccine effectiveness studies, in order to evaluate which

Bhutan’s national and also the oldest newspaper named ‘Kuensel’ from the Kuensel Corporation Limited published a story featuring, our support to the Bhutanese government in evaluating new vaccines through an economic evaluation, in their issue of 28th August 2017 http://www.kuenselonline.com/moh-exp

To support government decision-making to address the COVID-19 outbreak, the National Data Management Center (NDMC) of the Ethiopia Public Health Institute (EPHI) conducted a systematic review of the economic evaluations of public health measures for the prevention and control of pandemics. The study

A website offering parents advice on vaccines has been ordered to remove information about the MMR jab after claiming it could be linked to autism.Babyjabs.co.uk said the three-in-one jab may be causing “up to 10%” of autism in children in the UK.But the Advertising Standards Authority ruled the cla

Cervical cancer is a global public health problem, with approximately 500,000 new cases are identified each year globally. The disease is the most common cancer in women in the developing world and its mortality is very high–nearly 300,000 per year, 80% of which are in resource-poor settings. Human papillomavirus (HPV) has been proven as a major

A model-based economic evaluation was performed to estimate costs as well as outcomes of vaccination with PCV10 and PCV13 compared to ‘no vaccination’. This study considered two commonly recommended regimens: two-dose primary series at 2 and 4 months of age plus a booster dose at age 13 months (2+1) and three-dose primary series at 2, 4 and 6 m

In 2008, Myanmar proposed the development of a Health System Strengthening (HSS) programme to the Global Alliance for Vaccines and Immunization (GAVI) and thus received funding and support for its initiative. The HSS framework aimed to shore up three main gaps which were identified: service delivery, programme coordination, and human resources. Ser

Department of Immunization, Vaccines and Biologicals, World Health Organization (WHO) ได้รับการสนับสนุนเงินทุนจาก Global Alliance for Vaccines and Immunization (GAVI) และ the Centers for Disease Control and Prevention (US CDC) เพื่อริเริ่มโครงการพั

This virtual workshop was provided for public health professionals, researchers, and policy makers from Ghana, Malawi, and Tanzania. The course covered topics such as political economy of vaccinology, vaccine policy and distribution, and the science of vaccines, with a specific focus on the COVID-19 pandemic and COVID-19 vaccines.